首页> 美国卫生研究院文献>Journal of Nucleic Acids >Cell-Specific Aptamers as Emerging Therapeutics
【2h】

Cell-Specific Aptamers as Emerging Therapeutics

机译:细胞特异性适体作为新兴疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aptamers are short nucleic acids that bind to defined targets with high affinity and specificity. The first aptamers have been selected about two decades ago by an in vitro process named SELEX (systematic evolution of ligands by exponential enrichment). Since then, numerous aptamers with specificities for a variety of targets from small molecules to proteins or even whole cells have been selected. Their applications range from biosensing and diagnostics to therapy and target-oriented drug delivery. More recently, selections using complex targets such as live cells have become feasible. This paper summarizes progress in cell-SELEX techniques and highlights recent developments, particularly in the field of medically relevant aptamers with a focus on therapeutic and drug-delivery applications.
机译:适体是短核酸,其以高亲和力和特异性结合限定的靶标。大约在二十年前,通过称为SELEX(通过指数富集的配体的系统进化)的体外方法选择了第一批适体。从那时起,已经选择了许多对从小分子到蛋白质甚至整个细胞具有多种靶标特异性的适体。它们的应用范围从生物传感和诊断到治疗和面向目标的药物输送。最近,使用诸如活细胞的复杂靶标进行选择已变得可行。本文总结了细胞SELEX技术的进展,并重点介绍了最近的发展,特别是在医学相关的适体领域,重点是治疗和药物递送应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号